Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037851 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
A Phase 2 study of Pulmonary Aspergillosis, sponsored by Pulmocide.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 19
- Study locations
NCT05037851: Completed Phase 2 study of Pulmonary Aspergillosis, sponsored by Pulmocide.
NCT05037851 is a Phase 2 study of Pulmonary Aspergillosis that has completed, run by Pulmocide. The registered enrollment target is 102 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037851, a Phase 2 study of Pulmonary Aspergillosis, has completed, sponsored by Pulmocide.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 19
- Study locations
Study Summary
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
Primary Outcome
Percentage of Participants Who Completed 12 Weeks of PC945 or Initial Standard of Care (SoC)
Conditions Studied
Interventions
- DRUG Standard of Care
- DRUG Opelconazole
Study Locations (19)
Texas
- Clinical Research Site - Dallas
- Clinical Research Site 1 - Houston
- Clinical Research Site 2 - Houston
- Clinical Research Site 3 - Houston
Pennsylvania
- Clinical Research Site - Philadelphia
- Clinical Research Site - Philadelphia
- Clinical Research Site - Pittsburgh
California
- Clinical Research Site - La Jolla
- Clinical Research Site - Los Angeles
Florida
- Clinical Research Site - Jacksonville
- Clinical Research Site - Tampa
New York
- Clinical Research Site - New York
- Clinical Research Site - The Bronx
Other
- Clinical Research Site - Edmonton
- Clinical Research Site - Toronto
Arizona
- Clinical Research Site - Phoenix
Illinois
- Clinical Research Site - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 2 |
What the finished NCT05037851 record still lists
NCT05037851 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Pulmonary Aspergillosis appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT05037851 lists 19 locations in 10 states (Texas, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT05037851 about?
NCT05037851 is a clinical study titled "A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)". A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
What is the current status of trial NCT05037851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2021-11-19. Estimated completion is 2023-11-13.
What conditions does trial NCT05037851 study?
This clinical trial studies the following conditions: Pulmonary Aspergillosis.
What interventions are being tested in trial NCT05037851?
The interventions under investigation include: Standard of Care (DRUG), Opelconazole (DRUG).
Who is sponsoring clinical trial NCT05037851?
This trial is sponsored by Pulmocide, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05037851 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05037851's enrollment target sits among peer trials
102 668th of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI